Get the Stockscreener App
94.51
0.94%
0.88
After Hours:
94.35
-0.16
-0.17%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $94.51, with a volume of 8.05M.
It is up +0.94% in the last 24 hours and up +5.21% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$93.63
Open:
$94.14
24h Volume:
8.05M
Relative Volume:
1.53
Market Cap:
$293.03B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
31.39
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
-0.47%
1M Performance:
+5.21%
6M Performance:
+32.87%
1Y Performance:
+43.79%
1-Day Range:
$92.78
$94.53
1-Week Range:
$92.78
$96.51
52-Week Range:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
94.51 | 290.31B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewswire Inc.
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
AstraZeneca acquires AI firm to boost research - breakingthenews.net
Risks Report: What technical charts say about AstraZeneca PLC Depositary Receipt stockJuly 2025 Fed Impact & Weekly Return Optimization Plans - moha.gov.vn
AstraZeneca (AZN) Joins in Groundbreaking Genetic Research Initiative - GuruFocus
AstraZeneca (AZN) Progresses with Phase 3 TROPION-Lung17 Trial - GuruFocus
AstraZeneca (AZN) Set for Removal from Several Key Nasdaq Indexes - GuruFocus
AstraZeneca to be replaced by Walmart in the Nasdaq-100 index — Check dates - The Financial Express
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $215.25 - 富途牛牛
The Truth About AstraZeneca plc: Wall Street Sleeper Stock Or Overhyped Dinosaur? - AD HOC NEWS
The Truth About AstraZeneca plc: Is This Pharma Giant Still Worth Your Money? - AD HOC NEWS
Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) – Here’s Why - Insider Monkey
AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next - TechStock²
Walmart to join Nasdaq 100 from January 20 as AstraZeneca exits the index - MSN
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Walmart to Join Nasdaq 100 Index on January 20 as AstraZeneca Exits - scanx.trade
AstraZeneca: Oncology Dominance Justifies New All-Time Highs (NASDAQ:AZN) - Seeking Alpha
Walmart Set to Enter Nasdaq 100 on January 20, Replacing AstraZeneca - Bitget
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca - MSN
Walmart joins Nasdaq 100, $19 billion investment surge coming - Cryptopolitan
Walmart set to join Nasdaq 100 on January 20 as AstraZeneca drops out - Business Standard
Walmart to join Nasdaq 100 on Jan 20 as AstraZeneca exits - The Edge Malaysia
Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits - Bloomberg.com
Walmart to replace Astrazeneca on Nasdaq-100 on Jan 20 - marketscreener.com
Walmart to replace Astrazeneca on Nasdaq-100 - marketscreener.com
Can AstraZeneca PLC (ZEG) stock sustain institutional flowsJuly 2025 Chart Watch & Fast Entry High Yield Tips - ulpravda.ru
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
Can AstraZeneca PLC (Common Stock) (ZEGA) stock sustain breakout momentumRisk Management & Real-Time Stock Price Movement Reports - ulpravda.ru
Pharmacy XD Launches Nationally Licensed Direct-to-Patient Mail Order Pharmacy and Distribution Platform - Benzinga
AstraZeneca Taps Rick Suarez as US President & Head of the US Biopharmaceuticals Business Unit - Contract Pharma
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Yahoo Finance
AstraZeneca names insider Rick Suarez as head of US biopharmaceuticals unit - Reuters
ASTRAZENECA : Gets a Buy rating from Berenberg - MarketScreener
AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit - marketscreener.com
AstraZeneca names Rick Suarez as US president to lead $50 billion investment By Investing.com - Investing.com UK
Why AstraZeneca is putting $50B behind a new US boss - Stock Titan
BofA Securities Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $221.55 - 富途牛牛
AstraZeneca plc Announces Executive Changes , Effective March 1, 2026 - marketscreener.com
Is It Too Late To Consider AstraZeneca (LSE:AZN) After A 35% One-Year Rally? - Yahoo Finance UK
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters - MSN
Will AstraZeneca PLC (Common Stock) (ZEGA) stock profit from AI boomShort Selling Opportunities & Affordable Market Trading - ulpravda.ru
BostonGene teams up with AstraZeneca on AI-driven oncology - The Pharma Letter
Barclays Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $221.55 - 富途牛牛
My time working with the manufacturer of the AstraZeneca drug substance - substack.com
BostonGene, AstraZeneca Partner to Advance Oncology Drug Development - Contract Pharma
Check out AstraZeneca PLC's stock price (AZN-GB) in real time - CNBC
Check out AstraZeneca PLC's stock price (AZN) in real time - CNBC
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):